June 28, 2019 10:32 AM EDT

MiMedx is in trouble, again; Pfizer's Avastin biosimilar wins FDA approval

Natalie Grover

Reporter

→ The controversial MiMedx has dug itself a deeper hole. Senior officials at the wound care company, which has long been criticized for its business …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

MiMedx is in trouble, again; Pfizer's Avastin biosimilar wins FDA approval

Natalie Grover

Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

Updated: Trump administration halts more than $750M in funds for Moderna’s bird flu vaccine

PepGen ditches Duchenne programs after mid-stage fail, switches to previously halted muscle wasting therapy

Exclusive: Movement disorder biotech Vima steps onto scene with $60M

Oric locks down cash for Phase 3 prostate cancer trial with early data in hand

From weeks to days: how Aizon Intelligent Agents transform pharma validation

MiMedx is in trou­ble, again; Pfiz­er's Avastin biosim­i­lar wins FDA ap­proval

Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

MiMedx is in trouble, again; Pfizer's Avastin biosimilar wins FDA approval